EXACT Therapeutics announces grant of immunotherapy patent

25 Sep 2024 09:00 CEST

Oslo, Norway, September 25, 2024 - EXACT Therapeutics AS (Euronext Growth:
EXTX), a clinical stage precision medicine company utilizing the power of
ultrasound to enable targeted drug delivery in oncology, has been informed that
the Intellectual Property Office in United Kingdom will today grant EXACT its
United Kingdom Patent No: 2 605 996 entitled “Enhancement of Treatment with
Immunotherapeutic Agents”.

The granted patent covers EXACT’s proprietary Acoustic Cluster Therapy (ACT®) in
combination with immunotherapy in cancer and autoimmune disease patients.

Per Walday, CEO of EXACT comments, ”We are very pleased with the granting of
this important patent in its first territory. Expanding our patent protection is
a core strategy, reflecting the remarkable innovation coming out from our labs.
In addition, it supports our strategic oncology focus.”

For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

About EXACT Therapeutics:
EXACT is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement – Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement – with the potential to enable or significantly amplify the
clinical utility of a wide range of therapeutic agents across a multitude of
indications including within oncology (chemotherapy, immunotherapy) and brain
diseases. www.exact-tx.com

About ACT®:
• ACT is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.
• ACT is being tested in the clinic and has released positive interim data. It
is supported by a strong and broad preclinical package demonstrating therapeutic
enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as
well as blood-brain barrier penetration.
• Initial focus of the company is oncology. The ACT platform has potential
across many therapeutic areas (including CNS, immunotherapy) and product
classes.

Forward looking statements:
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.

More information:
Access the news on Oslo Bors NewsWeb site

628471_240925 EXTX IO patent.pdf